Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) gefitinib and erlotinib benefit some non–small cell lung cancer (NSCLC) patients, but most do not respond (primary resistance) and those who initially respond eventually progress (acquired resistance). EGFR TKI res...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Naumov, George N., Nilsson, Monique B., Cascone, Tina, Briggs, Alexandra, Straume, Oddbjorn, Akslen, Lars A., Lifshits, Eugene, Byers, Lauren Averett, Xu, Li, Wu, Hua-kang, Jänne, Pasi, Kobayashi, Susumu, Halmos, Balazs, Tenen, Daniel, Tang, Xi M., Engelman, Jeffrey, Yeap, Beow, Folkman, Judah, Johnson, Bruce E., Heymach, John V.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2893040/
https://ncbi.nlm.nih.gov/pubmed/19447865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2904
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky